Symbols

GRTS(Delisted)

Gritstone bio·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 0

Revenue Beats Expectation

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About GRTS

Gritstone Bio, Inc.

A tumor-specific cancer immunotherapies developer

Industry

Established Date

Listing Date

09/28/2018

Exchange

NASDAQ Stock Exchange

Full-time Employees

231

Fiscal Year Ends

12-31

Website

www.gritstonebio.com

Security Type

Common stock

Office address

5959 Horton Street, Suite 300, Emeryville, CA 94608

Business

Introduction

Gritstone bio, Inc., was incorporated in Delaware in August 2015. The company is a clinical-stage biotechnology company focused on combining immunological insights with proprietary technologies and capabilities to develop next-generation vaccines. The company discovers, develops, manufactures and delivers vaccine-based immunotherapy drug candidates for cancer and infectious diseases. The company's goal is to unlock stronger, longer-lasting immunity by leveraging vaccine innovations.

Company Financials

EPS

GRTS has released its 2024 Q2 earnings. EPS was reported at -0.16, versus the expected -0.28, beating expectations. The chart below visualizes how GRTS has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

GRTS has released its 2024 Q2 earnings report, with revenue of 921.00K, reflecting a YoY change of -52.89%, and net profit of -23.40M, showing a YoY change of 33.64%. The Sankey diagram below clearly presents GRTS's revenue sources and cost distribution.